Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CHEMI SPA

Home Clinical Trial Sponsors and OrganizationsCHEMI SPA

CHEMI SPA

VIA DEI LAVORATORI 54, Cinisello Balsamo, Milano, Italy

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

6

2 active

Approvals

9

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

3

50.0%

Phase 2

2

33.3%

Trial Status Distribution

Active, not recruiting

2

33.3%

Completed

4

66.7%

Clinical Trials

Trials sponsored by this organization (6)

Study for the LF-PB (30mg) efficacy evaluation on seroma incidence and duration after axillary dissection in patient with breast cancer

Active, not recruiting

Jan 202072 participants

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

Oct 201548 participants

Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.

Aug 201447 participants

A Single-Dose Trial to Examine the Within Subject Variability of Clexane® in Healthy Adults Under Fasting Conditions

Mar 201414 participants

Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea

Nov 2012114 participants

A randomized double-blind study, performed with the use of placebo, to assess the efficacy of the drug LF-PB at different doses to treat linforrea after removal of axillary lymph nodes in patients with breast cancer.

Active, not recruiting

Approvals

Approvals by Agency

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

9

Approvals

Recent Approvals

HEPAXANE 4.000 UI (40 MG)/0,4 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

HEPAXANE 12.000 UI (120 MG)/0,8 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

HEPAXANE 10.000 UI (100 MG)/1 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

HEPAXANE 2.000 UI (20 MG)/0,2 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

HEPAXANE 8.000 UI (80 MG)/0,8 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

HEPAXANE 15.000 UI (150 MG)/1 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

HEPAXANE 6.000 UI (60 MG)/0,6 ML SOLUCION INYECTABLE EN JERINGA PRECARGADA

MUSTINAL 2.5 MG/ML POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION EFG

STEOZOL 4 mg/5 ml CONCENTRADO PARA SOLUCION PARA PERFUSION EN JERINGA PRECARGADA

News

No news articles found

On this page

Overview
Clinical Trials6
Approvals9
News

Back to Organizations